SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:30 p.m. PT.
A copy of the company’s presentation will be made available on the insitro website following the event.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. These data are used to develop ML models that expand insitro’s data tensor via imputation, uncover underlying biologic state, and elucidate high-impact genetic modulators of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics, and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology, and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech, and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.
